Drugs & Targets Abbvie said Health Canada issued a Notice of Compliance with Conditions for Venclexta October 14, 2016Vol.42 No.38
Drugs & Targets Foundation Medicine, Inc. announces new clinical markers added to FoundationOne and FoundationOne Heme products October 14, 2016Vol.42 No.38
Drugs & Targets Genentech receives second Breakthrough Therapy Designation from FDA for Alecensa October 14, 2016Vol.42 No.38
Drugs & Targets The US Oncology Network selects Myriad Genetics as its preferred provider laboratory for hereditary cancer testing October 14, 2016Vol.42 No.38
Drugs & Targets Gamida Cell says FDA has granted Breakthrough Therapy Designation to NiCord October 14, 2016Vol.42 No.38
Drugs & Targets NICE recommends Eribulin for locally advanced metastatic breast cancer October 04, 2016Vol.42 No.41
Drugs & Targets Novogen and Genentech enter in commercialization agreement got glioblastoma multiforme drug candidate October 04, 2016Vol.42 No.41
Drugs & Targets Pronai Therapeutics obtains exclusive license to develop and commercialize PNT737 September 30, 2016Vol.42 No.36
Drugs & Targets Multiple Myeloma Research Foundation Contributes Data to NCI Genomic Data Commons September 30, 2016Vol.42 No.36
Drugs & Targets Prix Galien Foundation announces “Discovery of the Decade” nominees September 30, 2016Vol.42 No.36
